About eTheRNA ImmunotherapieseTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
Founder and CSO: Kris Thielemans
CEO: Dirk Reyn
CMO: Karl-Josef Kallen
Please click here for eTheRNA job opportunities.
Please click here for clinical trial information.
Tweets by eTheRNA
13 articles with eTheRNA Immunotherapies
6/18/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
eTheRNA Raises EUR 34 Million in Series B Financing to Accelerate Multiple mRNA Therapeutic Development Programs Through to Clinical Proof of Concept
eTheRNA immunotherapies NV, a clinical-stage company developing immunotherapies from its proprietary mRNA TriMix platform for the treatment of cancer and infectious diseases, announced that it has successfully raised Euro 34 million in a Series B equity financing round.
4/23/2020Biopharma and life sciences groups from across the globe provide updates on their business and pipelines.
3/26/2020Pharma and life sciences companies from across the globe provide updates on their pipelines and business practices.
eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine for High Risk Populations
eTheRNA Immunotherapies nv announced that a consortium has been formed with North American and European partners to develop a novel mRNA vaccine against CoV-2 and preclinical development has started.
Although the weekend was filled with news out of the American Society of Clinical Oncology Annual Meeting, here’s a roundup of some of the top clinical trial news from earlier last week.
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
Across parts of Europe, Asia and the rest of the globe, pharma and biotech companies have made strides and deals to advance their pipelines and technologies this week.
eTheRNA opens state-of-the-art manufacturing facility in Belgium to support the development of its TriMix-based mRNA cancer immunotherapies
eTheRNA immunotherapies announces the opening of a state-of-the-art mRNA manufacturing facility enabling the production of mRNA immunotherapies.
8/16/2018BioNTech, headquartered in Mainz, Germany, and Pfizer, based in New York City, signed a multi-year research-and-development deal to develop mRNA-based flu vaccines.
eTheRNA Immunotherapies Awarded €1 Million Grant From Flanders Innovation & Entrepreneurship To Further Upgrade Its State-Of-The-Art Production Process For Trimix MRNA Immunotherapies
eTheRNA Immunotherapies Advances In-Vivo mRNA Cancer Immunotherapy Into First Oncology Clinical Studies